GSK (GSK) said Monday that the European Commission has approved Jemperli in combination with chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
This approval expands the previous indication for Jemperli plus chemotherapy in the European Union to include patients with mismatch repair proficient or microsatellite stable tumors, the company said.
The approval is based on results from the first part of the RUBY phase 3 trial, which showed a clinically meaningful and statistically significant overall survival benefit in the patients with a 31% reduction in risk of detah compared with chemotherapy alone.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。